Despite positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from pharmacy benefit managers. Such companies are often https://keithedtj928268.theisblog.com/42456241/the-drug-faces-is-dealing-with-pharmacy-benefit-manager-hurdles-a-review-of-access-disputes